


## APPENDIX 17B: combination therapy forest plots

The forest plots for combined psychological-pharmacological treatments are referenced 'Combo xx.xx' in the evidence profiles (appendix 18) and summary evidence profiles in the chapters.

Combo 01.01 aggression measures .....	2
Combo 02.01 anger measures .....	2
Combo 03.01 anxiety measures .....	2
Combo 04.01 depression measures (self-rated) .....	3
Combo 04.02 depression measures (clinician-rated) .....	3
Combo 05.01 global functioning measures.....	3
Combo 06.01 quality of life measures .....	4
Combo 07.01 self-harm/suicidality .....	4
Combo 08.01 service use measures.....	5
Combo 09.01 antidepressants: leaving treatment early for any reason.....	5
Combo 09.02 antipsychotics: leaving treatment early for any reason .....	5
Combo 10.01 antidepressants: leaving treatment early due to side effects .....	6
Combo 10.02 antipsychotics: leaving treatment early due to side effects .....	6
Combo 11.01 antidepressants: number of participants reporting side effects .....	6
Combo 11.02 antipsychotics: number of participants reporting side effects.....	7
Combo 12.01 antipsychotics: weight change.....	7
Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures .....	7
Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures .....	8
Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures .....	8
Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures.....	9
Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures .....	9
Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability .....	10
Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures .....	10
Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability .....	11
Combo 16.01 olanzapine + DBT versus placebo: efficacy measures .....	11
Combo 16.02 olanzapine + DBT versus placebo: service use measures .....	12
Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures .....	12
Combo 16.04 olanzapine + DBT versus placebo: side effects .....	12


## Combo 01.01 aggression measures

Review: BPD combination pharmacology-psychology  
 Comparison: 01 Aggression measures  
 Outcome: 01 Clinician-rated measures




## Combo 02.01 anger measures

Review: BPD combination pharmacology-psychology  
 Comparison: 02 Anger measures  
 Outcome: 01 STAXI - total (12 weeks)




## Combo 03.01 anxiety measures

Review: BPD combination pharmacology-psychology  
 Comparison: 03 Anxiety measures  
 Outcome: 01 Clinician-rated measures (endpoint)




## Combo 04.01 depression measures (self-rated)

Review: BPD combination pharmacology-psychology  
 Comparison: 04 Depression measures  
 Outcome: 01 Self-rated measures (endpoint): combination treatments




## Combo 04.02 depression measures (clinician-rated)

Review: BPD combination pharmacology-psychology  
 Comparison: 04 Depression measures  
 Outcome: 02 Clinician-rated measures (endpoint): combination treatments




## Combo 05.01 global functioning measures

Review: BPD combination pharmacology-psychology  
 Comparison: 05 Global functioning measures  
 Outcome: 01 GAS/GAF




## Combo 06.01 quality of life measures

Review: BPD combination pharmacology-psychology  
 Comparison: 06 Quality of life measures  
 Outcome: 01 Fluoxetine + IPT vs fluoxetine or fluoxetine + CT




## Combo 07.01 self-harm/suicidality

Review: BPD combination pharmacology-psychology  
 Comparison: 07 Self-harm/suicidality  
 Outcome: 01 Self-harm/suicidality continuous measures




## Combo 08.01 service use measures

Review: BPD combination pharmacology-psychology  
 Comparison: 08 Service use  
 Outcome: 01 Olanzapine + DBT vs placebo + DBT: Number of visits to emergency psychiatric services (12 weeks)




## Combo 09.01 antidepressants: leaving treatment early for any reason

Review: BPD combination pharmacology-psychology  
 Comparison: 09 Leaving treatment early for any reason  
 Outcome: 01 Antidepressants (non-placebo comparisons)




## Combo 09.02 antipsychotics: leaving treatment early for any reason

Review: BPD combination pharmacology-psychology  
 Comparison: 09 Leaving treatment early for any reason  
 Outcome: 02 Antipsychotics (non-placebo comparisons)




## Combo 10.01 antidepressants: leaving treatment early due to side effects

Review: BPD combination pharmacology-psychology  
 Comparison: 10 Leaving treatment early due to side effects  
 Outcome: 01 Antidepressants (non-placebo comparisons)




## Combo 10.02 antipsychotics: leaving treatment early due to side effects

Review: BPD combination pharmacology-psychology  
 Comparison: 10 Leaving treatment early due to side effects  
 Outcome: 02 Antipsychotics (non-placebo comparisons)




## Combo 11.01 antidepressants: number of participants reporting side effects

Review: BPD combination pharmacology-psychology  
 Comparison: 11 Number of participants reporting side effects  
 Outcome: 01 Antidepressants (non-placebo comparisons)




## Combo 11.02 antipsychotics: number of participants reporting side effects

Review: BPD combination pharmacology-psychology  
 Comparison: 11 Number of participants reporting side effects  
 Outcome: 02 Antipsychotics (non-placebo comparisons)




## Combo 12.01 antipsychotics: weight change

Review: BPD combination pharmacology-psychology  
 Comparison: 12 Side effects: weight or weight change (kg)  
 Outcome: 01 Antipsychotics




## Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures

Review: BPD combination pharmacology-psychology  
 Comparison: 13 Fluoxetine + IPT versus fluoxetine  
 Outcome: 01 Efficacy measures




## Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures

Review: BPD combination pharmacology-psychology  
 Comparison: 13 Fluoxetine + IPT versus fluoxetine  
 Outcome: 02 QOL: Fluoxetine vs fluoxetine + IPT



## Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures


Review: BPD combination pharmacology-psychology  
 Comparison: 13 Fluoxetine + IPT versus fluoxetine  
 Outcome: 03 Tolerability and acceptability data






## Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures

Review: BPD combination pharmacology-psychology  
 Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT  
 Outcome: 01 Efficacy measures




## Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures

Review: BPD combination pharmacology-psychology  
 Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT  
 Outcome: 02 QOL: Fluoxetine vs fluoxetine + IPT + CT




## Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability

Review: BPD combination pharmacology-psychology  
 Comparison: 14 Fluoxetine + IPT versus fluoxetine + CT  
 Outcome: 03 Tolerability and acceptability data




## Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures

Review: BPD combination pharmacology-psychology  
 Comparison: 15 Fluoxetine + DBT versus placebo  
 Outcome: 01 Efficacy measures




## Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability

Review: BPD combination pharmacology-psychology  
 Comparison: 15 Fluoxetine + DBT versus placebo  
 Outcome: 03 Tolerability and acceptability data




## Combo 16.01 olanzapine + DBT versus placebo: efficacy measures

Review: BPD combination pharmacology-psychology  
 Comparison: 16 Olanzapine + DBT versus placebo  
 Outcome: 01 Efficacy measures




## Combo 16.02 olanzapine + DBT versus placebo: service use measures

Review: BPD combination pharmacology-psychology  
 Comparison: 16 Olanzapine + DBT versus placebo  
 Outcome: 02 Service use



## Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures

Review: BPD combination pharmacology-psychology  
 Comparison: 16 Olanzapine + DBT versus placebo  
 Outcome: 03 Tolerability and acceptability data



## Combo 16.04 olanzapine + DBT versus placebo: side effects

Review: BPD combination pharmacology-psychology  
 Comparison: 16 Olanzapine + DBT versus placebo  
 Outcome: 04 Side effects

